Myeloablative Preparative Regimen ( DrugBank: - )

3 diseases

ID	Disease name (Link within this page)	Number of trials
62	Paroxysmal nocturnal hemoglobinuria	2
65	Primary immunodeficiency	1
284	Diamond-Blackfan anemia	1

62. Paroxysmal nocturnal hemoglobinuria

Clinical trials : 271 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179359 (ClinicalTrials.gov)	September 2, 2014	27/6/2014	Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders	Sickle Cell Disease;Transfusion Dependent Alpha- or Beta- Thalassemia;Diamond Blackfan Anemia;Paroxysmal Nocturnal Hemoglobinuria;Glanzmann Thrombasthenia;Severe Congenital Neutropenia;Shwachman-Diamond Syndrome;Non-Malignant Hematologic Disorders	Drug: Reduced Toxicity Ablative Regimen;Drug: Reduced Intensity Preparative Regimen;Drug: Myeloablative Preparative Regimen	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	55 Years	All	25	N/A	United States
2	NCT00587054 (ClinicalTrials.gov)	June 2001	21/12/2007	Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders	Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders	Allogeneic Stem Cell Transplant;Leukemia;Non-Hodgkins;Lymphoblastic Lymphoma;Myelodysplastic Syndrome;Paroxysmal Nocturnal Hemoglobinuria (PNH)	Drug: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant	Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)	Completed	18 Years	55 Years	All	129	Phase 2	United States

65. Primary immunodeficiency

Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179359 (ClinicalTrials.gov)	September 2, 2014	27/6/2014	Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders	Sickle Cell Disease;Transfusion Dependent Alpha- or Beta- Thalassemia;Diamond Blackfan Anemia;Paroxysmal Nocturnal Hemoglobinuria;Glanzmann Thrombasthenia;Severe Congenital Neutropenia;Shwachman-Diamond Syndrome;Non-Malignant Hematologic Disorders	Drug: Reduced Toxicity Ablative Regimen;Drug: Reduced Intensity Preparative Regimen;Drug: Myeloablative Preparative Regimen	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	55 Years	All	25	N/A	United States

284. Diamond-Blackfan anemia

Clinical trials : 37 / Drugs : 110 - (DrugBank : 34) / Drug target genes : 23 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02179359 (ClinicalTrials.gov)	September 2, 2014	27/6/2014	Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies	MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders	Sickle Cell Disease;Transfusion Dependent Alpha- or Beta- Thalassemia;Diamond Blackfan Anemia;Paroxysmal Nocturnal Hemoglobinuria;Glanzmann Thrombasthenia;Severe Congenital Neutropenia;Shwachman-Diamond Syndrome;Non-Malignant Hematologic Disorders	Drug: Reduced Toxicity Ablative Regimen;Drug: Reduced Intensity Preparative Regimen;Drug: Myeloablative Preparative Regimen	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	55 Years	All	25	N/A	United States